These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 29146569)

  • 1. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
    Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
    Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW; Huang D
    Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.
    Lew TE; Seymour JF
    J Hematol Oncol; 2022 Jun; 15(1):75. PubMed ID: 35659041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
    Yalniz FF; Wierda WG
    Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
    Liu J; Li S; Wang Q; Feng Y; Xing H; Yang X; Guo Y; Guo Y; Sun H; Liu X; Yang S; Mei Z; Zhu Y; Cheng Z; Chen S; Xu M; Zhang W; Wan N; Wang J; Ma Y; Zhang S; Luan X; Xu A; Li L; Wang H; Yang X; Hong Y; Xue H; Yuan X; Hu N; Song X; Wang Z; Liu X; Wang L; Liu Y
    Blood; 2024 May; 143(18):1825-1836. PubMed ID: 38211332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
    Madhavan K; Balakrishnan I; Lakshmanachetty S; Pierce A; Sanford B; Fosmire S; Elajaili HB; Walker F; Wang D; Nozik ES; Mitra SS; Dahl NA; Vibhakar R; Venkataraman S
    Clin Cancer Res; 2022 Jun; 28(11):2409-2424. PubMed ID: 35344040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
    Vogler M; Walter HS; Dyer MJS
    Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for Venetoclax in Myelodysplastic Syndromes.
    Garcia JS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic development and current uses of BCL-2 inhibition.
    Roberts AW
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 13. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
    Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
    Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
    Ahn IE; Davids MS
    Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
    Cang S; Iragavarapu C; Savooji J; Song Y; Liu D
    J Hematol Oncol; 2015 Nov; 8():129. PubMed ID: 26589495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathways and mechanisms of venetoclax resistance.
    Bose P; Gandhi V; Konopleva M
    Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic inhibition of BCL-2 and related family members.
    Levy MA; Claxton DF
    Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
    Choi JH; Bogenberger JM; Tibes R
    Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.